Nasdaq · CIK 0001664710
KROS Keros Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 24, 2025. Close $11.95 on Oct 9, 2026, +21% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
KROSOct 9, 2026 · close 11.95
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Keros Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | ADAR1 Capital Management, LLC owner buy | $9.5M 934,258 shares | +27% | - |
Transactions
The last 25 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By ADAR1 Partners, LP | -100 | $60.00 | $6,000 | 4,392,637 | Jun 24, 2025 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By ADAR1 Partners, LP | -1,400 | $70.00 | $98k | 4,391,237 | Jun 24, 2025 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By Spearhead Insurance Solutions IDF, LLC | -200 | $70.00 | $14k | 743,358 | Jun 24, 2025 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By ADAR1 Partners, LP | -1 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By ADAR1 Partners, LP | -14 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By Spearhead Insurance Solutions IDF, LLC | -2 | $0.00 | $0 | 0 | Jun 24, 2025 |
| May 16, 2025 | ADAR1 Capital Management, LLC owner | EExpiration of short derivative Put Option (obligation to buy)derivativeindirect: By ADAR1 Partners, LP | -300 | $0.00 | $0 | 0 | Jun 12, 2025 |
| May 16, 2025 | ADAR1 Capital Management, LLC owner | EExpiration of short derivative Put Option (obligation to buy)derivativeindirect: By ADAR1 Partners, LP | -836 | $0.00 | $0 | 0 | Jun 12, 2025 |
| May 16, 2025 | ADAR1 Capital Management, LLC owner | EExpiration of short derivative Put Option (obligation to buy)derivativeindirect: By Spearhead Insurance Solutions IDF, LLC | -178 | $0.00 | $0 | 0 | Jun 12, 2025 |
| Jun 4, 2025 | Nima Farzan director | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 5,250 | Jun 6, 2025 |
| Jun 4, 2025 | Jean Jacques Bienaime director | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 5,450 | Jun 6, 2025 |
| Jun 4, 2025 | Nima Farzan director | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
| Jun 4, 2025 | Jean Jacques Bienaime director | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +18,560 | $9.40 | $174k | 3,493,404 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: By Spearhead Insurance Solutions IDF, LLC | +16,365 | $9.40 | $154k | 743,558 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +325,000 | $9.86 | $3.2M | 3,818,404 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +500,000 | $10.33 | $5.2M | 4,318,404 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +74,333 | $10.33 | $768k | 4,392,737 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | JOther Cash-Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -325,000 | - | - | 624,333 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | JOther Cash-Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -500,000 | - | - | 124,333 | Apr 11, 2025 |
| Apr 9, 2025 | ADAR1 Capital Management, LLC owner | JOther Cash Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -74,333 | - | - | 50,000 | Apr 11, 2025 |
| Feb 18, 2025 | Yung H. Chyung Chief Medical Officer | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 44,000 | Feb 19, 2025 |
| Feb 18, 2025 | Christopher Rovaldi Chief Operating Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 60,000 | Feb 19, 2025 |
| Feb 18, 2025 | Keith Regnante CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 44,000 | Feb 19, 2025 |
| Nov 8, 2024 | Yung H. Chyung Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- ADAR1 Capital Management, LLCowner
- Jean Jacques Bienaimedirector
- Yung H. ChyungChief Medical Officer
- Nima Farzandirector
- Keith RegnanteCHIEF FINANCIAL OFFICER
- Christopher RovaldiChief Operating Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.